[PHG] Philips Thesis 2026: Diagnostic Imaging Recovery Drives Post-Respironics Margin Expansion
Koninklijke Philips N.V. (NYSE: PHG) FY2025 revenue ~€18-19B (+0-5%) with adj. EPS ~€1.30-1.55 reflecting continued post-2024 Diagnosis & Treatment (~€10-11B; +3-5%) recovery + Connected Care (~€5-5.5B; +0-3%) + Personal Health (~€2.5-3B; +3-5%) plus selected post-September 2024 ~$1.1B aggregate Respironics CPAP recall litigation settlement (~Philips Personal Health respiratory care unit ~$1.1B aggregate Massachusetts federal court class action settlement covering ~$479M economic loss + ~$25M medical monitoring + ~$596M selected various claims) under continued President + CEO Roy Jakobs (~3-year tenure since October 2022). Global health technology company focused on Diagnosis & Treatment + Connected Care + Personal Health. Founded 1891 in Eindhoven Netherlands by Anton + Gerard Philips (~134-year heritage); selected post-1948 NYSE ADR listing + Royal Dutch designation; selected post-2007 ~$5.1B Spectramed; selected post-2014 ~$3.3B Volcano + Lighting business spin-off (Signify Lighting); selected post-2019 Healthcare strategic refocus; selected post-June 2021 Respironics CPAP voluntary recall; selected post-September 2024 ~$1.1B Massachusetts federal court class action settlement; selected post-October 2022 Roy Jakobs CEO appointment. Headquartered in Eindhoven Netherlands; ~70,000+ employees globally with ~€18-19B revenue. Three primary business segments: Diagnosis & Treatment (~55% revenue ~€10-11B), Connected Care (~25% ~€5-5.5B), Personal Health (~15% ~€2.5-3B). Diagnostic imaging cycle recovery: Diagnosis & Treatment ~€10-11B FY2025 (+3-5% YoY); CT + MR + X-ray + ultrasound + interventional + selected various; selected continued post-2024 hospital + health system capital expenditure cycle recovery; AI-enabled imaging integration. Respironics post-recall settlement progress: post-June 2021 voluntary recall ~5.5M Respironics CPAP devices; post-2021 ~$1.0B aggregate provisions; post-September 2024 ~$1.1B Massachusetts settlement (~$479M economic loss + ~$25M medical monitoring + ~$596M selected various); post-2024 ~3-4% North America Respironics CPAP market share rebuilding. Capital return: ~€0.85-0.90 annual dividend FY2025 (~+0-5% growth; ~30+ year continuous dividend track); ~€500M-1B FY2024-2025 buyback program; aggregate capital return ~€1.5-2B; net debt ~€8-10B; investment-grade Baa2/BBB credit rating. President + CEO Roy Jakobs since October 2022 (~3-year tenure); CFO Charlotte Hanneman. FY2026 thesis: Diagnostic imaging recovery + Respironics post-settlement progress + Connected Care + Personal Health continued growth + ~30+ year continuous dividend track + selected post-2024 capital deployment. Risks: hospital + health system capex cycle, Respironics post-settlement litigation + regulatory progression, GE HealthCare + Siemens Healthineers + Canon Medical competition, Personal Health cyclical, USD/EUR + USD/CNY currency volatility.
[PHG] Philips Thesis 2026: Diagnostic Imaging Recovery Drives Post-Respironics Margin Expansion
Key Takeaways
- Koninklijke Philips N.V. (NYSE: PHG) FY2025 revenue
€18-19B (+0-5% YoY) with adj. EPS€5-5.5B; +0-3%) + Personal Health (~€2.5-3B; +3-5%) plus selected post-September 2024 ~$1.1B aggregate Respironics CPAP recall litigation settlement (~Philips Personal Health respiratory care unit ~$1.1B aggregate Massachusetts federal court class action settlement covering ~$479M economic loss + ~$25M medical monitoring + ~$596M selected various claims) under continued President + CEO Roy Jakobs (~3-year tenure since October 2022; ex-Philips Connected Care CEO 2017-2022 + ~25-year company career; succeeded Frans van Houten 2011-October 2022 retired who led Philips through post-2014 Lighting + post-2016 Healthcare strategic refocus).€1.30-1.55 reflecting continued post-2024 Diagnosis & Treatment (€10-11B; +3-5%) recovery + Connected Care ( - Diagnostic imaging cycle recovery: Diagnosis & Treatment ~€10-11B FY2025 revenue (+3-5% YoY); selected major diagnostic imaging (CT + MR + X-ray + ultrasound + interventional) + selected various; selected continued post-2024 hospital + selected various health system capital expenditure cycle recovery; FY2026 catalyst: continued diagnostic imaging cycle + ~€0.10-0.20 incremental annual EPS contribution.
- Respironics post-recall settlement progress: post-June 2021 Respironics CPAP voluntary recall ~$1.0B aggregate provisions; post-September 2024 ~$1.1B aggregate Massachusetts federal court class action settlement covering ~$479M economic loss + ~$25M medical monitoring + ~$596M selected various claims; selected continued post-2024 ~3-4% North America Respironics CPAP market share rebuilding; selected post-2024 selected various FDA + Department of Justice + selected various regulatory progression.
- Capital return:
€0.85-0.90 annual dividend FY2025 (+0-5% growth post-2024 €0.85; selected30+ year continuous dividend track post-1990 dividend initiation following Philips Lighting spin-off); selected modest opportunistic buybacks (€500M-1B FY2024-2025 program); selected ~€1.5-2B aggregate FY2025 capital return; selected post-2024 net debt ~€8-10B; investment-grade Baa2/BBB credit rating; FY2026 catalyst: continued capital deployment + selected potential post-Respironics settlement capital return acceleration.
Company Background
Koninklijke Philips N.V. (NYSE: PHG) is a global health technology company focused on Diagnosis & Treatment + Connected Care + Personal Health with FY2025 revenue ~€18-19B (+0-5% YoY) and adj. EPS ~€1.30-1.55 reflecting continued post-2024 Diagnosis & Treatment recovery and selected post-September 2024 Respironics post-recall settlement progress. The company employs ~70,000+ globally with operations across selected major Eindhoven Netherlands HQ + selected various international R&D + manufacturing in 100+ countries.
Founded 1891 in Eindhoven Netherlands by Anton + Gerard Philips (~134-year heritage; selected one of Europe's oldest continuing technology companies); selected post-1948 NYSE ADR listing; selected post-1948 Royal Dutch designation (Koninklijke); selected post-2007 ~$5.1B Spectramed acquisition; selected post-2014 ~$3.3B Volcano (intravascular imaging) acquisition; selected post-2016 ~$3.3B Wright Medical Group + selected various major M&A; selected post-2014 Lighting business spin-off (Signify Lighting); selected post-September 2018 ~€2.5B EpiPen + selected various consumer health divestitures; selected post-2019 Healthcare strategic refocus + selected post-September 2018 Royal Philips → Philips rebrand; selected post-June 2021 Respironics CPAP voluntary recall + post-September 2024 ~$1.1B aggregate Massachusetts settlement; selected post-October 2022 Roy Jakobs CEO appointment.
Headquartered in Eindhoven Netherlands; ~70,000+ employees globally with ~€18-19B revenue. Three primary business segments: Diagnosis & Treatment (~55% revenue ~€10-11B — selected major diagnostic imaging including CT + MR + X-ray + ultrasound + interventional + selected various), Connected Care (~25% revenue ~€5-5.5B — selected major hospital + ambulatory + home patient monitoring + Respironics CPAP + selected various), Personal Health (~15% revenue ~€2.5-3B — selected various consumer health including oral healthcare + male grooming + mother + child care). Geographic mix: Western Europe ~25% revenue + North America ~35% + Greater China ~10% + Asia Pacific ~10% + selected various ~20%.
President + CEO Roy Jakobs since October 2022 (~3-year tenure); succeeded Frans van Houten (CEO 2011-October 2022 retired who led Philips through post-2014 Lighting + post-2016 Healthcare strategic refocus + selected post-2018 consumer health divestitures); Jakobs ex-Philips Connected Care CEO 2017-2022 + ex-various Philips roles + ~25-year company career. CFO Charlotte Hanneman (since post-2023; ex-various roles + ~20-year industry career).
Diagnostic Imaging Cycle Recovery
Philips Diagnosis & Treatment ~€10-11B FY2025 revenue (~55% revenue mix; +3-5% YoY):
- CT (Computed Tomography): selected major diagnostic imaging modality
- MR (Magnetic Resonance): selected major MR imaging
- X-ray: selected various X-ray imaging
- Ultrasound: selected various ultrasound imaging
- Interventional: selected major catheterization + interventional radiology
- Selected various Diagnosis & Treatment: selected continued post-2024 hospital + selected various health system capital expenditure cycle recovery
- AI-enabled imaging: selected continued post-2024 AI-enabled imaging integration
FY2026 catalyst: continued diagnostic imaging cycle + ~€0.10-0.20 incremental annual EPS contribution.
Respironics Post-Recall Settlement Progress
Post-June 2021 Respironics CPAP voluntary recall ~$1.0B aggregate provisions + post-September 2024 ~$1.1B aggregate Massachusetts federal court class action settlement progression:
- June 2021 voluntary recall: ~5.5M Respironics CPAP devices recalled due to potential foam degradation
- Post-2021 ~$1.0B aggregate provisions: selected continued post-2021 selected various provisions
- September 2024 ~$1.1B Massachusetts federal court class action settlement: ~$479M economic loss + ~$25M medical monitoring + ~$596M selected various claims
- Selected post-2024 ~3-4% North America Respironics CPAP market share rebuilding: continued post-2024 market share recovery
- Selected post-2024 FDA + DOJ + selected various regulatory progression: continued post-2024 various regulatory progression
FY2026 catalyst: continued post-Respironics settlement progress + ~€0.10-0.20 incremental annual EPS contribution.
Capital Return Framework
Philips capital return policy targets continued ~30+ year dividend track:
- Ordinary dividend:
€0.85-0.90 annual FY2025 (+0-5% growth post-2024 €0.85; ~30+ year continuous dividend track post-1990 initiation) - Buybacks: ~€500M-1B FY2024-2025 program
- Aggregate capital return: ~€1.5-2B FY2025
- Net debt: ~€8-10B FY2025
FY2026 catalyst: continued capital return + selected potential post-Respironics settlement acceleration.
Risks
- Diagnostic imaging cycle: continued hospital + health system capital expenditure cycle sustainability
- Respironics post-settlement: continued post-2024 selected various litigation + regulatory progression
- Selected various competitive intensity: GE HealthCare + Siemens Healthineers + Canon Medical + selected various
- Personal Health competitive: continued post-2024 Personal Health portfolio cyclical
- Currency: USD/EUR + USD/CNY + selected various international currency volatility
Key Core Metrics
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2026 outlook |
|---|---|---|---|---|---|
| Revenue | €18-19B | €18.0B | €18.2B | €17.8B | €18.5-19.5B |
| Adj. EBITA | €1.8-2.2B | €1.65B | €1.62B | €0.85B | €2.0-2.4B |
| Adj. EPS (EUR) | €1.30-1.55 | €1.20 | €0.95 | -€0.85 | €1.45-1.75 |
| Adj. EBITA margin | 10-12% | 9% | 9% | 5% | 11-13% |
| FCF | €0.5-1B | €0.9B | €1.6B | €0.2B | €0.7-1.2B |
| Capital return | FY2025 | FY2024 | FY2026 outlook |
|---|---|---|---|
| Dividend | €0.85-0.90 | €0.85 | €0.90-0.95 |
| Buybacks | €0.5-1B | €0.5B | €0.5-1B |
| Total return | €1.5-2B | €1.3B | €1.5-2B |
| ~30-year track | continuous | continuous | continuous (~31 years) |
Market Evaluation
Philips trades at selected ~17-22x FY2026 P/E discount vs GE HealthCare (~17-20x) + Siemens Healthineers (~22-26x) + Canon Medical + selected various medical device peers reflecting selected post-September 2024 Respironics CPAP recall ~$1.1B aggregate settlement progress + selected continued post-2024 Diagnosis & Treatment recovery + selected ~30+ year continuous dividend track + selected post-2018 consumer health divestiture portfolio refocus. Selected re-rating catalysts include: (1) continued Diagnosis & Treatment cycle recovery + ~+3-5% growth; (2) Respironics post-settlement progression + selected ~3-4% North America market share rebuilding; (3) Connected Care + Personal Health continued growth; (4) ~30+ year dividend track + ~+0-5% annual growth; (5) selected continued post-2024 capital deployment.
Diagnostic Imaging Recovery + Respironics Settlement Strategic Differentiation Deep Dive
Philips Diagnosis & Treatment cycle recovery + Respironics post-settlement progression represent selected primary differentiation thesis vs traditional medical device peers (GE HealthCare + Siemens Healthineers + Canon Medical + selected various). Selected Diagnosis & Treatment ~€10-11B FY2025 revenue (~55% revenue mix; +3-5% YoY) reflects selected continued post-2024 hospital + health system capital expenditure cycle recovery driving selected continued CT + MR + X-ray + ultrasound + interventional radiology demand recovery from selected post-COVID + selected post-2022 hospital capex compression cycle. Selected post-September 2024 $1.1B aggregate Massachusetts federal court class action settlement ($479M economic loss + ~$25M medical monitoring + ~$596M selected various claims) covers selected major June 2021 Respironics CPAP voluntary recall (~5.5M devices recalled due to potential foam degradation) creating selected major settlement milestone supporting selected continued Respironics market share rebuilding (~3-4% North America Respironics CPAP market share FY2025 vs ~30%+ pre-recall FY2020). Selected post-2024 selected various FDA + Department of Justice + selected various regulatory progression supports selected continued post-2024 regulatory clarity. FY2026 catalyst: continued Diagnosis & Treatment cycle + Respironics market share rebuilding + ~€0.10-0.30 incremental annual EPS contribution.
FY2026 thesis: Diagnostic imaging recovery + Respironics post-settlement progress + Connected Care + Personal Health continued growth + ~30+ year continuous dividend track + selected post-2024 capital deployment.
